G protein subunit alpha o1Genealiases: DEE17 · EIEE17 · G-ALPHA-o · GNAO · HG1G · NEDIM
Q-omics provides the consensus-scored GNAO1 profile across patient tissues and cancer cell-line models. GNAO1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, GNAO1 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, GNAO1 protein abundance shows 31,037 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, BLCA, and GBM as cancer lineages where GNAO1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GNAO1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GNAO1 survival associations across molecular data types. GNAO1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GNAO1 RNA expression–survival associations across cancer types. High GNAO1 expression shows unfavorable associations in KIRP and BLCA, but favorable associations in KIRC, LUAD, LGG and PAAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for GNAO1 RNA expression.
This table summarizes GNAO1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GNAO1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GNAO1 shows lower tumor expression in BLCA, COAD, LIHC, READ and UCEC and higher tumor expression in HNSC. The BLCA box plot shows higher GNAO1 RNA expression in normal versus tumor tissue (log2 FC = −3.784, t-test p < 0.001).
This table shows molecular features associated with GNAO1 in patient tissues and cancer cell lines. In patient samples, GNAO1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GNAO1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
